Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study.

Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF.

Clin Infect Dis. 2009 Feb 15;48(4):e41-6. doi: 10.1086/596552.

PMID:
19133801
2.

Nitazoxanide for the treatment of Clostridium difficile colitis.

Musher DM, Logan N, Hamill RJ, Dupont HL, Lentnek A, Gupta A, Rossignol JF.

Clin Infect Dis. 2006 Aug 15;43(4):421-7. Epub 2006 Jul 11.

PMID:
16838229
3.

Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide.

Musher DM, Logan N, Mehendiratta V, Melgarejo NA, Garud S, Hamill RJ.

J Antimicrob Chemother. 2007 Apr;59(4):705-10. Epub 2007 Mar 2.

PMID:
17337513
4.

Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.

Warren CA, van Opstal EJ, Riggins MS, Li Y, Moore JH, Kolling GL, Guerrant RL, Hoffman PS.

Antimicrob Agents Chemother. 2013 Feb;57(2):689-96. doi: 10.1128/AAC.00877-12. Epub 2012 Nov 12.

5.

Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial.

Gerding DN, Meyer T, Lee C, Cohen SH, Murthy UK, Poirier A, Van Schooneveld TC, Pardi DS, Ramos A, Barron MA, Chen H, Villano S.

JAMA. 2015 May 5;313(17):1719-27. doi: 10.1001/jama.2015.3725.

PMID:
25942722
6.

Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.

Al-Nassir WN, Sethi AK, Nerandzic MM, Bobulsky GS, Jump RL, Donskey CJ.

Clin Infect Dis. 2008 Jul 1;47(1):56-62. doi: 10.1086/588293.

PMID:
18491964
7.

Antibiotic treatment for Clostridium difficile-associated diarrhea in adults.

Nelson R.

Cochrane Database Syst Rev. 2007 Jul 18;(3):CD004610. Review. Update in: Cochrane Database Syst Rev. 2011;(9):CD004610.

PMID:
17636768
8.
9.

Fidaxomicin versus vancomycin for Clostridium difficile infection.

Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK; OPT-80-003 Clinical Study Group.

N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812.

10.

Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.

Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL.

Clin Infect Dis. 2012 Aug;55 Suppl 2:S154-61. doi: 10.1093/cid/cis462.

11.

Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting.

Venugopal AA, Riederer K, Patel SM, Szpunar S, Jahamy H, Valenti S, Shemes SP, Khatib R, Johnson LB.

Scand J Infect Dis. 2012 Apr;44(4):243-9. doi: 10.3109/00365548.2011.631029. Epub 2011 Nov 13.

PMID:
22077148
12.

A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity.

Zar FA, Bakkanagari SR, Moorthi KM, Davis MB.

Clin Infect Dis. 2007 Aug 1;45(3):302-7. Epub 2007 Jun 19.

PMID:
17599306
13.

Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.

Johnson S, Louie TJ, Gerding DN, Cornely OA, Chasan-Taber S, Fitts D, Gelone SP, Broom C, Davidson DM; Polymer Alternative for CDI Treatment (PACT) investigators.

Clin Infect Dis. 2014 Aug 1;59(3):345-54. doi: 10.1093/cid/ciu313. Epub 2014 May 5.

PMID:
24799326
14.

In vitro and in vivo activities of nitazoxanide against Clostridium difficile.

McVay CS, Rolfe RD.

Antimicrob Agents Chemother. 2000 Sep;44(9):2254-8.

15.

Nitazoxanide versus metronidazole for Clostridium difficile-associated colitis.

Young JD, Mangino JE, Stevenson KB, Koletar SL.

Clin Infect Dis. 2007 Jan 1;44(1):152; author reply 152-4. No abstract available.

PMID:
17143841
16.

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.

Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S; OPT-80-004 Clinical Study Group.

Lancet Infect Dis. 2012 Apr;12(4):281-9. doi: 10.1016/S1473-3099(11)70374-7. Epub 2012 Feb 8.

PMID:
22321770
17.

Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial.

Hota SS, Sales V, Tomlinson G, Salpeter MJ, McGeer A, Coburn B, Guttman DS, Low DE, Poutanen SM.

Clin Infect Dis. 2017 Feb 1;64(3):265-271. doi: 10.1093/cid/ciw731. Epub 2016 Nov 9.

PMID:
28011612
18.

Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.

Louie T, Nord CE, Talbot GH, Wilcox M, Gerding DN, Buitrago M, Kracker H, Charef P, Cornely OA.

Antimicrob Agents Chemother. 2015 Oct;59(10):6266-73. doi: 10.1128/AAC.00504-15. Epub 2015 Jul 27.

19.

Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection.

Wenisch JM, Schmid D, Kuo HW, Allerberger F, Michl V, Tesik P, Tucek G, Laferl H, Wenisch C.

Antimicrob Agents Chemother. 2012 Apr;56(4):1974-8. doi: 10.1128/AAC.05647-11. Epub 2012 Jan 17.

20.

Vancomycin for the treatment of Clostridium difficile Infection: for whom is this expensive bullet really magic?

Pepin J.

Clin Infect Dis. 2008 May 15;46(10):1493-8. doi: 10.1086/587656.

PMID:
18419481

Supplemental Content

Support Center